Clinical Trial

A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is an open-label, multi-center phase II clinical trial aimed to evaluat the safety and preliminary efficacy of JS212 combination therapy in patients with advanced esophageal squamous cell carcinoma (ESCC).
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-23
Trial Details
NCT Number NCT07484724
Lead Sponsor Shanghai Junshi Bioscience Co., Ltd.
Conditions Advanced Esophageal Squamous Cell Carcinoma
Enrollment 280 participants
Start Date 2026-04-13
Primary Completion 2027-06-30 (estimated)
Study Completion 2028-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-22